Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (Note: Metadata listed "Abeona Therapeutics," but the filing text identifies the registrant as Access Pharmaceuticals, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2010
Business Overview: An emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company has one approved product (MuGard for oral mucositis), two products in Phase 2 clinical development (ProLindac for cancer, Thiarabine for leukemia/lymphoma), and several pre-clinical candidates (CobOral, CobaCyte). The company relies on strategic alliances and licensing for commercialization and funding.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $481,000 | $352,000 |
| Net Loss | $(7,537,000) | $(17,340,000) |
| Net Loss Allocable to Common Stockholders | $(9,328,000) | $(19,226,000) |
| Loss Per Share (Basic & Diluted) | $(0.60) | $(1.63) |
| Research & Development Expenses | $3,349,000 | $2,657,000 |
| General & Administrative Expenses | $4,511,000 | $7,112,000 |
| Cash and Cash Equivalents (Year End) | $7,033,000 | $607,000 |
| Working Capital Deficit | $(6,136,000) | $(7,949,000) |
| Accumulated Deficit | $(251,135,000) | $(241,807,000) |
| Convertible Debt (Current) | $5,500,000 | $0 |
Liquidity: The company reported a net cash burn rate of approximately $567,000 per month for 2010. Management projected cash resources would be sufficient to fund operations into the first quarter of 2012.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $129,000 (37%) driven by higher licensing revenue ($347k vs $315k), the introduction of sponsored R&D revenue ($58k vs $0), and increased MuGard royalties ($76k vs $37k).
- Expense Reduction: General and administrative expenses decreased by $2.6 million, primarily due to reduced consulting fees, lower potential liquidated damages, and fewer stock option grants for G&A employees.
- Derivative Accounting Impact: The company recorded a $4.6 million gain on the change in fair value of warrant derivatives in 2010, compared to a $7.2 million loss in 2009. Conversely, a new $5.8 million loss was recorded in 2010 related to the fair value of preferred stock derivatives due to anti-dilution provisions.
- Financing Activity: The company raised approximately $13.1 million in net proceeds from two registered direct offerings of common stock and warrants in January and December 2010. This significantly increased cash balances from $607,000 to $7.0 million.
- Debt Reclassification: A $5.5 million convertible note, previously long-term, was reclassified as a current liability due to its maturity date of September 13, 2011.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The independent auditor included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit. The company requires additional capital to continue operations beyond early 2012.
- Debt Maturity Risk: The company has a $5.5 million unsecured convertible note due September 13, 2011. Management plans to extend the due date, but failure to do so could result in default and insufficient capital to continue operations.
- Internal Control Weakness: Management identified a material weakness in internal control over financial reporting. All financial reporting is performed by the Chief Financial Officer, resulting in a lack of segregation of duties and insufficient accounting technical expertise.
- Product Outlook: MuGard was launched in the U.S. in Q4 2010. ProLindac initiated a Phase 2 combination trial in Q4 2010. Thiarabine initiated Phase 2 trials in adult AML/ALL. The company does not expect significant revenues in the short term.
- Unusual Items: The company received $1.479 million in government grants (Qualifying Therapeutic Discovery Project Grants) in 2010, recorded as miscellaneous income. Additionally, $534,000 in negotiated payables and write-offs contributed to miscellaneous income.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured additional financing to cover the $5.5 million debt due in September 2011 and sustain operations beyond Q1 2012.
- Derivative Liabilities: Monitor the fair value of warrant and preferred stock derivatives, as fluctuations in stock price can cause significant non-cash gains or losses impacting net income.
- Commercialization of MuGard: Assess actual sales performance and reimbursement success of MuGard in the U.S. following its Q4 2010 launch.
- Internal Controls: Confirm if the company has hired additional accounting staff to remediate the material weakness regarding segregation of duties.
- Dilution Risk: Review the terms of the Series A Preferred Stock and outstanding warrants, which contain anti-dilution provisions that could lower conversion/exercise prices if stock is issued below $2.55, significantly diluting common shareholders.